Lenalidomide Maintenance Therapy Post Autologous Transplant for Hodgkins Lymphoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

28 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-04-28

Study Completion Date

2021-03-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study to evaluate the feasibility of lenalidomide maintenance therapy in patients with relapsed Hodgkin lymphoma after autologous transplant

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma

NCT00540007

Hodgkin Disease

COMPLETED PHASE2

Maintenance Lenalidomide in Lymphoma

NCT01575860

Lymphoma

COMPLETED PHASE1/PHASE2

Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma

NCT01035463

Anaplastic Large Cell Lymphoma, ALK-Negative Recurrent Anaplastic Large Cell Lymphoma Recurrent Mantle Cell Lymphoma +3 more

COMPLETED PHASE1/PHASE2

Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory Hodgkin's Lymphoma

NCT00478959

Hodgkin Disease

COMPLETED PHASE2

Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma

NCT02568553

Recurrent Burkitt Lymphoma Recurrent Diffuse Large B-Cell Lymphoma Recurrent Grade 1 Follicular Lymphoma +23 more

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary Objectives

-To evaluate the feasibility of lenalidomide maintenance therapy in patients with relapsed Hodgkin lymphoma after autologous stem cell transplant, as measured by dropout rate.

Secondary Objectives

* To assess overall survival, event free survival, and progression free survival.
* To establish the adverse event profile of long-term maintenance therapy with lenalidomide in this patient population.
* To assess the conversion of partial response/stable disease post-ASCT to complete response.
* To evaluate changes in immune cell number and function and plasma proteins before, during, and after lenalidomide therapy (correlative studies).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hodgkin Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm 1

Lenalidomide 15 mg/day Cycle 1 (28 days).

If no unacceptable side effects Cycle 2 (28 days) will be lenalidomide 20 mg/day.

If no unacceptable side effects Cycles 3 thru 18 (28 days for each cycle) will be lenalidomide 25 mg/day.

Group Type EXPERIMENTAL

Lenalidomide

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lenalidomide

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Revlimid

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient must have histologically documented classical Hodgkin lymphoma that is recurrent or refractory to standard chemotherapy.
* Core biopsies are acceptable if they contain adequate tissue for primary diagnosis and immunophenotyping. If the original diagnostic specimen is not available, relapsed or refractory specimens may be used. Bone marrow biopsies as the sole means of diagnosis are not acceptable; however, they may be used in conjunction with nodal biopsies. Fine needle aspirates (FNA) are not acceptable. Pathology reports must be submitted with the appropriate CRFs, and the actual biopsy specimens are not requested for central review. Patients with cHL have one of the following WHO subtypes:

* Nodular sclerosis Hodgkin lymphoma
* Lymphocyte-rich Hodgkin lymphoma
* Mixed cellularity Hodgkin lymphoma
* Lymphocyte-deplete Hodgkin lymphoma cHL patients without one of these subtypes designated cHL not otherwise specified are also eligible.

NOTE: Patients with nodular lymphocyte-predominant HL are not eligible.

* Patient must have undergone autologous stem cell transplant (ASCT) between 60 and 90 days prior to study registration.
* Patient must be ≥ 18 years old.
* Patient must have an ECOG performance status of ≤ 2 at study entry.
* Patient must have adequate hematologic, renal, and hepatic function as defined by:

* Absolute neutrophil count ≥ 1000 / μL
* Platelets ≥ 30,000 / μL
* Serum creatinine ≤ 1.5 X institution upper limit of normal (ULN)
* Total bilirubin ≤ 1.5 mg/dL
* AST (SGOT) and ALT (SGPT) ≤ 3 x ULN (if not attributed to cHL)
* Patient must be disease free of prior malignancies for ≥ 5 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix or breast.
* Patient must understand and voluntarily sign an informed consent form.
* Patient must be able to adhere to the study visit schedule and other protocol requirements.
* If a female of childbearing potential (FCBP), patient must agree to use two reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual intercourse during the following time periods related to this study: 1) for at least 28 days before starting study drug; 2) while participating in the study; and 3) for at least 28 days after discontinuation from the study. The two methods of reliable contraception must include one highly effective method (i.e. intrauterine device (IUD), hormonal \[birth control pills, injections, or implants\], tubal ligation, partner's vasectomy) and one additional effective (barrier) method (i.e. latex condom, diaphragm, cervical cap). FCBP must be referred to a qualified provider of contraceptive methods if needed
* A FCBP is defined as a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).
* A FCBP must have two negative pregnancy tests (sensitivity of at least 50 mIU/mL) prior to starting study drug. The first pregnancy test must be performed within 10-14 days prior to the start of study drug and the second pregnancy test must be performed within 24 hours prior to prescribing the study drug. The subject may not receive study drug until the Investigator has verified that the results of these pregnancy tests are negative.
* If male, patient must agree to use a latex condom during sexual contact with FCBP while participating in the study and for at least 28 days following discontinuation from the study even if he has undergone a successful vasectomy.
* Patient must be able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to ASA may use warfarin or low molecular weight heparin).
* Patient must be registered into the mandatory Revlimid REMS® program and be willing and able to comply with the requirements of Revlimid REMS®.

Exclusion Criteria

* Patient who has undergone allogeneic stem cell transplantation.
* Patient who shows evidence of progressive disease during salvage chemotherapy or following ASCT.
* Patient has any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent him/her from signing the informed consent form.
* Patient has any condition, including the presence of laboratory abnormalities, which places him/her at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
* Patient has used any other anti-cancer drug or therapy, including experimental, within 30 days of initiation of lenalidomide treatment (radiation therapy is allowed within 30 days).
* Patient has known hypersensitivity to thalidomide.
* Patient developed erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.
* Patient has any prior use of lenalidomide.
* Patient is known to be positive for HIV or infectious hepatitis, type A, B, or C.
* Patient is pregnant or breastfeeding.
* Patient has concurrent use of other anti-cancer agents or treatments.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No